Compass Financial Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
Compass Financial Management's CRSP Position: Q3 2026 in Review
Compass Financial Management opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 450 shares worth $24.9K. The stake represents ﹤0.01% of the portfolio and ranks #894 among its holdings.
504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- Compass Financial Management held 450 shares of CRISPR Therapeutics worth $24.9K as of Q3 2026.
- CRISPR Therapeutics was a new Compass Financial Management position in Q3 2026.
- CRISPR Therapeutics made up ﹤0.01% of Compass Financial Management's portfolio in Q3 2026, its #894 holding.
- 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on Compass Financial Management's 13F filing for Q3 2026, filed 30 Oct 2026.